MedTrace Logo

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

NCT03669757 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-10-26

No results posted yet for this study

Summary

To assess safety and tolerability after treatment with LEO 134310 cutaneous solution.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

LEO 134310

Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

DRUG

LEO 134310

Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

DRUG

LEO 134310

Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

DRUG

LEO 134310

Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

DRUG

LEO 134310 vehicle

Active substance: none

DRUG

0.1% betamethasone valerate ointment (class III steroid)

Active substance: betamethasone valerate

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Study Director · LEO Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-27
Primary Completion
2019-02-01
Completion
2019-02-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03669757 on ClinicalTrials.gov